HRD Tests for Ovarian cancER
ConditionOvarian Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorCentre Francois Baclesse
About this trial
The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy.
To determine HRD status, 2 separate tests will be performed in the study:
1. Giscar assay : developed by the sponsor 2. myChoice assay
If one or two tests identifies a HRD status :
a PARP inhibitor treatment may be initiated according to current recommendations
Eligibility criteria
Qualifiers
Patient aged 18-year or more
Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
Newly diagnosed advanced (International Federation of Gynecology and Obstetrics [FIGO] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy
Tumor tissue must be available for HRD analyses (FFPE tissue block) and
Disqualifiers
Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
Non epithelial or borderline ovarian cancer
Other tumor, for which the treatment may interfere with the ovarian cancer treatment and/or that may have a major impact on prognosis
Exclusive palliative setting
Trial design
Treatments tested in this trial
- tests to determine HRD status
Treatment groups
88 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov